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cell signallingDystrophin is a 427 kDa sub-membrane cytoskeletal protein, associated with the inner surface membrane and
incorporated in a large macromolecular complex of proteins, the dystrophin-associated protein complex
(DAPC). In addition to dystrophin theDAPC is composed of dystroglycans, sarcoglycans, sarcospan, dystrobrevins
and syntrophin. This complex is thought to play a structural role in ensuring membrane stability and force trans-
duction during muscle contraction. The multiple binding sites and domains present in the DAPC confer the scaf-
fold of various signalling and channel proteins, which may implicate the DAPC in regulation of signalling
processes. The DAPC is thought for instance to anchor a variety of signalling molecules near their sites of action.
The dystroglycan complex may participate in the transduction of extracellular-mediated signals to the muscle
cytoskeleton, and β-dystroglycan was shown to be involved in MAPK and Rac1 small GTPase signalling. More
generally, dystroglycan is view as a cell surface receptor for extracellular matrix proteins. The adaptor proteins
syntrophin contribute to recruit and regulate various signalling proteins such as ion channels, into a mac-
romolecular complex. Although dystrophin and dystroglycan can be directly involved in signalling path-
ways, syntrophins play a central role in organizing signalplex anchored to the dystrophin scaffold. The
dystrophin associated complex, can bind up to four syntrophin through binding domains of dystrophin
and dystrobrevin, allowing the scaffold of multiple signalling proteins in close proximity. Multiple interac-
tions mediated by PH and PDZ domains of syntrophin also contribute to build a complete signalplex which
may include ion channels, such as voltage-gated sodium channels or TRPC cation channels, together with,
trimeric G protein, G protein-coupled receptor, plasma membrane calcium pump, and NOS, to enable efﬁcient
and regulated signal transduction and ion transport. This article is part of a Special Issue entitled: Reciprocal
inﬂuences between cell cytoskeleton and membrane channels, receptors and transporters. Guest Editor: Jean
Claude Hervé.
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Dystrophin is a 427 kDa cytoskeletal protein expressed from the DMD
gene defective in Duchenne muscular dystrophy [1,2]. The transcriptionnﬂuences between cell cytoskel-
Guest Editor: Jean Claude Hervé.
ights reserved.of the DMD gene is controlled by three independent promoters, the
Brain (B), muscle (M) and Purkinje (P) promoters reﬂecting the tissue
distribution of dystrophin expression [3]. The M promoter drives high
level of expression in striated skeletal and cardiac muscles [4]. The DMD
gene has also four internal promoters (R for retinal, B3 for Brain3, S for
Schwann cells, G for General) that give rise to shorter transcripts
encoding for truncated COOH-terminal isoforms. Splicing at a unique
ﬁrst exon generates dystrophin isoforms of 260 kDa (DP60), 140 kDa
(DP140), 116 kDa (DP116), and 71 kDa (DP71) [5–7]. These COOH-
636 B. Constantin / Biochimica et Biophysica Acta 1838 (2014) 635–642terminal dystrophin proteins contain some binding sites allowing in-
teraction with a number of dystrophin-associated proteins (DAP).
The 427 kDa dystrophin is a member of the β-spectrin/α-actinin pro-
tein family [8]. Based on sequence homology, this cytoskeletal protein is
thought to be organized into four distinct domains: (i) The amino-
terminal domain contains pair of calponin homology (CH)modules bind-
ing ﬁlamentous actin [9]; (ii) Adjacent to this region, the central rod do-
main is composed of more than 2800 amino acids building 24
homologous triple helical repeats and four hinge domains [8], which are
suggested to confer ﬂexibility to the protein; (iii) A third region is com-
posed of aWWdomain [10], which is a small β-sheetmotif that is usually
involved in intracellular signalling through the recognition of proline-rich
or phosphorylated linear peptide sequences. The WW domain of dystro-
phin recognizes a PPxY motif and is involved in the interaction with β-
dystroglycan. This WW domain is followed by a cystein-rich domain
with two EF-hand motifs [11] and two ZZ modules in series [12] binding
to calmodulin in a calcium-dependentmanner [13]; (iv) The COOH termi-
nus domain, which is unique to dystrophin and related protein [14] con-
tains two regions formingα-helical coiled coils [15] forming the binding
site for dystrobrevin. Dystrophin is a sub-membrane cytoskeletal
protein, i.e. associated with the inner surface membrane and incor-
porated in a large macromolecular complex of proteins, the
dystrophin-associated protein complex [16,17]. The demonstration
that dystrophin is linked through the membrane-spanning protein
complex to the extracellularmatrix (ECM) and to the actin cytoskeleton
through the amino-terminal domain [18], has originally led to the idea
that dystrophin played a structural role in ensuringmembrane stability
and force transduction during muscle contraction. This role was
thought to preclude membrane disruptions (micro-ruptures) and
non-speciﬁc leakages of ions and/or other biological components and
led to the “mechanical hypothesis” for DMD, inwhich the loss of dystro-
phin, and of the cytoskeleton-ECM linkage, could be the primer of the
progressive cellular necrosis (by over-activating calcium-dependent
proteases) observed in such a disease. Studies of transgenic mice ex-
pressing deleted dystrophin constructs suggested that the cystein-rich
domain with amino-terminal domain or portions of the rod domain
are minimally required for protecting mousemuscle against dystrophic
degeneration [19]. The dystrophin-related protein, utrophin, can func-
tionally compensate for the lack in dystrophin in mdx dystrophic
mouse and protect the muscle against degeneration [20,21]. Utrophin
shows signiﬁcant sequence homology with dystrophin and structural
similarities [14], which can also provide mechanical protection to the
skeletal muscle. However, utrophin does not anchor nNOs to sarcolem-
ma and cannot restore this signalling pathway as does the dystrophin/
syntrophin complex. Among dystrophin-related proteins with sequence
homology to dystrophin, the DRP2 and the dystrobrevins proteins only
have sequence similarity to the COOH-terminal regions of dystrophin
[22]. Dystrobrevins are encoded by two different genes, α and β, and
have signiﬁcant homology with the cysteine-rich domain of dystrophin
[23,24]. Alpha-dystrobrevin is expressed predominantly in muscle and
brain whereas β-dystrobrevin is expressed in non-muscle tissues,
which is abundant in the brain, kidney, lung and liver [25]. Knockout of
α-dystrobrevin results in progressive myopathy suggesting an essential
role in striated muscle [26]. Apart from dystrophin, utrophin and DAPC
the dystrobrevins have a set of speciﬁc binding partners involved in
structural integrity: syncoilin; dysbindin; desmuslin (also known
as β-synemin) and DAMAGE [25,27]. Dystrobrevins have also been
involved in intracellular signalling inmuscle and non-muscle tissues,
either directly, or through interaction with syntrophin [26,27], and
also by interaction with Regulatory Subunit of protein kinase A,
and Protein phosphatase 2A [28].
2. Dystrophin-associated protein complex (DAPC) and cell signalling
In addition to dystrophin the DAPC is composed of dystroglycans,
sarcoglycans, sarcospan, dystrobrevins and syntrophin. Discovery ofDAPC, referred to as the dystrophin–glycoprotein complex (DGC),
represented a major advancement in the understanding of the
DGC's function in skeletal muscle and provided further support for
the contraction-induced sarcolemma injury model underlying DMD
pathogenesis. In another hand, the DAPC has also been proposed to
constitute a putative cellular signalling complex by conferring the
scaffold for numerous signalling proteins. For instance, the ZZ mod-
ules in the cysteine-rich domain of dystrophin may represent a func-
tional calmodulin-binding site which could modulate the binding of
other dystrophin-associated protein in a calcium-dependent man-
ner. The multiple binding sites and domains present in the DAPC
confer the scaffold of various signalling and channel proteins,
which may implicate the DAPC in the regulation of signalling pro-
cesses. The DAPC is thought for instance to anchor a variety of signal-
ling molecules near their sites of action.
2.1. Dystroglycans
The single dystroglycan gene encodes for a precursor protein [29]
that undergoes posttranslational proteolytic cleavage, which produces
two noncovalantly subunits of the dystroglycan complex, α- and
β-dystroglycan [29–32]. In muscle, α-dystroglycan and β-dystroglycan
display a molecular mass of 156 kDa and 43 kDa respectively, whereas
in the Brain, the molecular mass of α-dystroglycan, identiﬁed as cranin
[33] is 120 kDa. Theα-dystroglycan is an extensively glycosylated ex-
tracellular protein [18,34] with two globular domains connected by
an extensible portion [35,36]. The glycoepitope of α-dystroglycan
mediates the binding of extracellular matrix components [34,37].
The dumbbell-shaped protein α-dystroglycan binds to the laminin
G domain in extracellular matrix components such as laminins,
agrin and perlecan. Biglycan binding to α-dystroglycan was also
demonstrated by coimmunoprecipitation with both native and re-
combinant α-dystroglycan [38]. The biglycan binding site was
mapped to the COOH-terminal third of α-dystroglycan. In muscle,
biglycan was detected at both synaptic and nonsynaptic regions.
The binding of biglycan to α-dystroglycan could act in concert
with, or as an alternative to, binding via the G-protein—containing
basal lamina proteins agrin, perlecan, and laminin, but the function
is unknown. However, biglycan null mice exhibits a mild dystrophic
phenotype and displays a selective reduction in the localization of
alpha-dystrobrevin-1 and -2, alpha- and beta1-syntrophin, and nNOS
at the sarcolemma [39]. Moreover, Biglycan protein injected into mus-
cle stably associateswith the sarcolemma and ECMand restores the sar-
colemmal expression of alpha-dystrobrevin-1 and -2, and beta1- and
beta2-syntrophin in biglycan null mice. Biglycan binding is thus impor-
tant for the stability of DAPC in the skeletal muscle. The β-dystroglycan
has a single transmembrane domain spanning the plasma membrane
and an extracellular amino-terminal extracellular domain binding to
the carboxy-terminal globular domain of α-dystroglycan [40,41]. The
COOH terminus on the cytoplasmic side contains several proline resi-
dues required for the binding to dystrophin, and binds directly to the
WW modules and the cystein-rich domain containing the EF and ZZ
modules [42–45]. A study indicates that a WW-like domain within
caveolin-3 [46] directly recognizes the extreme C terminus of β-
dystroglycan that contains a PPXYmotif. It was propose that interaction
of caveolin-3 with β-dystroglycan may competitively regulate the re-
cruitment of dystrophin to the plasma membrane.
The dystroglycan complex may participate in the transduction of
extracellular-mediated signals to the muscle cytoskeleton, and β-
dystroglycanwas shown to be involved inMAPK signalling. Laminin en-
gagement by dystroglycan is leading to the recruitment of a Grb2–Sos1
complex to dystroglycan [47]. The resulting downstream activation of
Rac1, activates JNK, through the Cdc42-Race effector p21 activated ki-
nase 1 (PAK1). Several studies performed in non-muscle cells implicate
dystroglycan in themodulation of ERK-MAPK signalling. The interaction
of β-dystroglycan with MEK and ERK [48] suggests dystroglycan may
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A role of dystrophin–dystroglycan complex in MAPK signalling in skel-
etal muscle was indirectly explored inmdx dystrophicmice lacking dys-
trophin. Some studies reported a higher ERK1/2 activation after a
mechanical stimulation [49] or following a chronic treadmill exercise
[50], suggesting that the loss of dystrophin–dystroglycan complex is re-
sponsible for an altered mechanotransduction. It was also reported that
disruption of laminin binding to α-dystroglycan induced apoptosis in
dystrophicmyotubes through a decreasedAkt activity [51]. Thismay ac-
count for a role of dystrophin–glycoprotein complex in survival signal.
However Akt was reported to be increased in two other studies on
mdx muscle deﬁcient in DAPC [52,53]. Dystroglycan is also involved in
various cellular processes including neuromuscular junction formation
through, in part, interaction of β-dystroglycan with rapsyn [54], a pe-
ripheral protein required for nicotinic acetylcholine receptor (AChR)
clustering. Rapsyn and dystroglycan interact in the postsynaptic
membrane reinforcing the notion that dystroglycan could be in-
volved in synaptogenesis. In vitro studies have also suggested that
β-dystroglycan interacts with growth factor receptor bound protein
2 (Grb2), when non-associated with dystrophin [55]. The Grb2/β-
dystroglycan association is mediated through β-dystroglycan
proline-rich domains and Grb2 src homology 3 domains. This inter-
action may be of biological importance in transducing signals arising
from the binding of dystroglycan to extracellular matrix proteins
[56] or in transferring information between the dystroglycan com-
plex and other signalling pathways [57]. Recent studies support a
model whereby dystroglycan serves as a receptor essential for the
initial binding of laminin on the cell surface [58]. New ﬁndings with-
in neurons reveal a fundamental role for dystroglycan in organizing
axon guidance cue distribution and function within the extracellular
matrix [59]: It was found that glycosylated dystroglycan binds directly to
the axon guidance cue Slit to organize its protein distribution in the ﬂoor
plate and the basement membrane, thereby regulating Slit-mediated
axon guidance. A nuclear import pathway for β-dystroglycan was also
recently reported and new ﬁndings imply that β-dystroglycan is a nucle-
ar scaffolding protein involved in nuclear organization and nuclear enve-
lope structure and functions in myoblasts [60]. More generally,
dystroglycan is view as a cell surface receptor for extracellular matrix
proteins, which is involved in cell polarity, matrix organization and me-
chanical stability of tissues [61–63]. Several studies documented the loss
of dystroglycan protein expression and glycosylation in a variety of can-
cer types [64,65], and it was recently proposed to be caused by a down
regulation of LARGE2 resulting in hypoglycosylation of α-dystroglycan
and loss of its ability to bind to laminin-111 [66].2.2. Sarcoglycans
The sarcoglycan complex is composed of α, β, γ and δ-sarcoglycan
isoforms encoded by separate genes [67–70] and of sarcospan [71].
Sarcoglycans are single transmembrane glycoproteins with N-terminus
oriented extracellularly for α-sarcoglycan and intracellularly for β, γ
and δ-sarcoglycans [67–70]. On the contrary, sarcospan is constitut-
ed of four transmembrane-spanning segments, which are homolo-
gous to the tetraspanin family [71]. Two other sarcoglycan have
been identify, ε-sarcoglycan, with homology to α-sarcoglycan [72],
and ξ-sarcoglycan, most homologous to γ and δ-sarcoglycan isoforms
[73]. The function of the sarcoglycan complex is not fully understood,
but it appears to strengthen interaction of β-dystroglycan with
α-dystroglycan and dystrophin [74]. Mutations in any of these four
glycosylated single-pass transmembrane proteins result in autosomal
recessive limb-girdle muscular dystrophy (LGMD-2C-2 F). In the ab-
sence of δ-sarcoglycan, such as in LGMD-2 F, the remaining sarcoglycan
members (α,β andγ) cannot assemble and are quickly degraded before
transport from the Golgi [75,76]. The absence of δ-sarcoglycan has also
been shown to reduce nNOS levels (neuronal nitric oxide synthase,which in turn regulates vasodilation during exercise), and increases
its displacement from the sarcolemma [77].
Biglycan was shown to be a ligand for two members of the
sarcoglycan complex and regulates their expression at discrete develop-
mental ages [78]. Small leucine-rich repeat (LRR) proteoglycan biglycan
binds to alpha- and gamma-sarcoglycan. Both biglycan proteoglycan as
well as biglycan polypeptide lacking glycosaminoglycan (GAG) side
chains are components of the dystrophin glycoprotein complex isolated
from the adult skeletal muscle membranes. Biglycan is an extracellular
component of signalling pathways that was shown to play a role in
the formation of stress ﬁbres in cultured cells in amanner that is depen-
dent on small GTPases [79] and also in muscle regeneration [80,81].
Sarcoglycans could thus be a pathway in skeletal muscle for mediating
the effects of biglycan during myogenesis and muscle regeneration.
Since defects in the sarcoglycan complex were also associated with
muscle dystrophies, one may also hypothesise that biglycan binding to
sarcoglycan is involved in transduction of cell survival signals.
Several studies on sarcoglycan function suggested a role in intra-
cellular signal transduction. For instance the cytoplasmic domain of
γ-sarcoglycan displays ﬁve tyrosine residues, whichmay be involved
in bidirectional signalling with integrin [82]. In another hand, the α-
sarcoglycan was reported to display ecto-ATPase activity [83], which
suggests that α-sarcoglycan may modulate the activity of P2X recep-
tors by buffering the extracellular ATP concentration. Sarcospan, a
25-kDa transmembrane protein, was the last component to be iden-
tiﬁed [71] and its function in skeletal muscle has been elusive. As
reviewed by Marshall and Crosbie-Watson [84], recent works
highlighted new signalling functions for sarcospan. Sarcospan improves
cell surface expression of the dystrophin– and utrophin–glycoprotein
complexes as well as α7β1 integrin, which are the three major
laminin-binding complexes in muscle. Moreover, sarcospan was pro-
posed to modulate utrophin protein levels at least in part through
Akt/p70S6K signalling pathways [85].2.3. Syntrophins
Syntrophins aremultigene family of intracellularmembrane-associated
adaptor proteins. The syntrophin family consists of ﬁve homologous
isoforms, α1-syntrophin, β1-syntrophin, β2-syntrophin, γ1-syntrophin
and γ2-syntrophin [86–89]. The different isoforms of syntrophin have
different cellular and sub-cellular localization suggesting a distinct
functional role. The α1-syntrophin linked to the DAPC and distributed
over the entire sarcolemma of skeletal muscle ﬁbres is mediating the
anchoring of neuronal nitric synthase (nNOS) to the sarcolemma and
the dystrophin complex [90,91]. The β2-syntrophin is exclusively re-
stricted to the neuromuscular junction [92]. The γ1-syntrophin has
been shown to be involved in cellular synaptic function by binding
and regulating sub-cellular localisation of diacylglycerol kinase ξ [93],
which catalyses the conversion of diacylglycerol (DAG) to phosphatidic
acid (PA). Both DAG and PA are lipid second messengers with roles in
actin organization for instance. This could confer a role in cell shape reg-
ulation through actin modelling and also in cell migration.
These scaffold proteins are characterized by the presence of a N-
terminal PH-1 domain (Plekstrin Homology) split in two halves (PHN
and PHC) by insertion of a PDZ domain (Post Synaptic Density protein-
95, Drosophila discs large protein, and the Zona occludens protein 1),
a second Plekstrin Homology domain (PH-2) and a C-terminal domain
unique to syntrophins (SU). [87,94]. The SU domain and PH-2 domain
interact with the carboxy terminus of dystrophin [95,96]. There are
two syntrophin binding sites in the carboxy terminus of dystrophin
and additional two sites on α-dystrobrevin [97], cytoplasmic proteins
sharing signiﬁcant homology with the carboxy-terminal domains of
dystrophin [98]. The presence of binding domains like PH, SU and PDZ
domain allow these scaffold proteins to interact with several other pro-
teins and lipids leading to the building of multi-protein/lipid signalling
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2.3.1. Syntrophins and signaling pathways
Syntrophins were shown to be involved in signalling pathways
necessary for the development and building of the neuromuscular
junctions: α1-syntrophin-knockout in mice shows that the scaffold-
ing protein plays an important role in neuromuscular junction mat-
uration [99,100], and during muscle regeneration [101], and the
density of acetylcholine receptors at the neuromuscular junction is
reduced in α1-syntrophin−/−mice [99]. The α/β2-syntrophin null
mice displays neuromuscular junctions that are structurally more
aberrant than those lacking only of α1-syntrophin [102].
The PH and PDZ domains of syntrophins were shown to bind various
proteins, whichmay implicate syntrophins in numerous signalling path-
ways and cell function. For instance, the NH2 terminus of PH1 domain
and the NH2 terminus of PDZ domain were shown to bind calmodulin
[103,104], a calcium binding protein transducing calcium signal in the
cell by interactingwith downstream target proteins. Signalling pathways
dependent on heterotrimeric G-proteINS may also interact with
syntrophins. The PH1N halfdomain was shown to interact with multiple
isoforms of Gα subunits [105], such as Gαs, Gαi, Gαo and Gαq subtypes.
The binding of Gα subunit of heterotrimeric G protein with syntrophin
suggests the scaffolding protein may regulate signalling pathways
dependent on G-coupled transmembrane receptors. For instance, in
COS-7 cells, down regulation of α1-syntrophin resulted in an en-
hanced cAMP production [105]. PH domains of other proteins were
shown to bind the βγ-subunits of the heterotrimeric G proteins
and proposed to be involved in localization of key signalling proteins
to appropriate membrane compartment. Isolated syntrophin was
also demonstrated to bind brain Gβγ-subunits [106], and the PDZ
domain-containing sequence of recombinant α-syntrophin was
required for binding Gβγ-subunits. This binding was shown to be
dependent on laminin-α-dystroglycan binding in skeletal muscle,
and to affect interaction of Gsαβγwith α-syntrophin [106]. Interest-
ingly, this interaction decreases the amount of active Gsα and was
suggested to inhibit Ca2+ through calcium channels. In addition,
α1-syntrophin interacts through the PDZ domain with the C-terminal
domain of α1-adrenergic receptors [107], which are G protein-coupled
receptors mediating physiological function in cardiovascular apparatus.
Moreover, mutation of the PDZ domain was shown to decrease inositol
phosphate formation in response to norepinephrine and to decrease
α1D-adrenergic receptor binding and expression [107]. These observa-
tions provided additional arguments about the role of syntrophins in
modulating G protein-coupled receptor function. Moreover, the
syntrophin–dystrophin complex in mouse aortic smooth muscle cells
was shown to associate with α1D-adrenergic receptor for building a
signalplex, playing an essential role in the regulation of α1D-
adrenergic receptor function and of vascular tone and blood pressure
[108]. Dystrophin, syntrophin, dystrobrevin and utrophin are interacting
proteins for α1D-adrenergic receptor, and the knock-out of multiple
syntrophin isoforms results in the complex loss ofα1D-adrenergic recep-
tor function in mouse aortic smooth muscle cells.
Syntrophin PDZ domain also binds an ETTF motif in neuronal nitric
oxide synthase (nNOS) that forms a β-ﬁnger [109]. In skeletal muscle, in-
teraction of nNOS withα1-syntrophin is mediated by PDZ domain [110],
and nNOS in brain also interacts with α1-syntrophin in speciﬁc neurons
[111]. Alpha1-syntrophin gene disruption results in the absence of
nNOS at the sarcolemma of skeletal muscle ﬁbres [112], and an in vivo
dominant-negative approach indicated that the PDZ domain is not re-
quired for plasma membrane association of α1-syntrophin, but is neces-
sary for the sarcolemmal localization of nNOS [91]. It is likely that α1-
syntrophin PDZdomain is required for proper functionof nNOS in skeletal
muscle, and itwas shown that localization of the enzyme to the sarcolem-
ma was important for regulating adrenergic-vasoconstriction in muscle
during activity [113,114]. Moreover, nNOS and α1-syntrophin wereshown to be parts of a macromolecular protein complex containing the
sarcolemmal calcium pump (PMCA) in cardiomyocytes [115]. A ternary
interaction between PMCA, α1-syntrophin and nNOS was proposed,
where the COOH-terminal tail of PMCA interacts with the PDZ domain
of nNOS and the linker region between the PH2 and SU domains of α1-
syntrophin are involved in binding an intracellular loop of PMCA. The
PMCA was shown to be a negative regulator of nNOS-dependent NO
production [115,116], and α1-syntrophin and PMCA were proposed to
synergistically moderate nNOS-activity. NO signalling is involved in dif-
ferent functions in the heart including contractility [117] and inward so-
dium currents [118]. In addition to NOS interaction, syntrophins have
been implicated in the regulation of various ion channels of the plasma
membrane such as voltage-operated sodium channels, and this usually
involved the PDZ domain of syntrophin.
2.3.2. Syntrophins and ion channels and membrane transporters
The PDZ domain from α1, β1 and β2 syntrophins was shown to
bind the C-terminal 10 amino acids of voltage-gated sodium chan-
nels from the skeletal (SkM1) and cardiac (SkM2) muscles [119].
This interaction was shown to be mediated by the direct interaction
of the PDZ domain to the (S/T)XV C terminus of the sodium channel.
The cardiac voltage-gated channel NaV1.5 was also reported to asso-
ciate through C-terminus with dystrophin, and this interaction was
mediated by α and β-syntrophins in a PDZ-dependent manner
[120]. The study of deﬁcient mdx mice suggested that the disruption of
the dystrophin/syntrophin/NaV1.5 channel resulted in the alteration of
expression and function of sodium channels, with consequences on ECG
properties. Interestingly, inward sodium currents of cardiomyocytes
were described to be modulated by the level of S-nitrosylation of NaV1.5
sodium channels, which was dependent on association of the channels
with the PMCA–nNOS complex through interaction with α1-syntrophin
[121]. An A390Vmutation of α1-syntrophin selectively disrupted the as-
sociation of PMCAwith the complex and increased nitrosylation of NaV1.5
sodium channels, likely through an increasedNOS activity. The disruption
of the complex increased amplitude of peak and late sodium currents and
was associated with a long QT syndrome [121], which can be due in rare
case to α1-syntrophin mutation. Altogether, these studies show that the
scaffold of α1-syntrophin is required for maintaining a PMCA/nNOS/
NaV1.5 complex, which is a key regulator of sodium currents in
cardiomyocytes and as a consequence of cardiac rhythm.
This study, together with the work of Ueda and collaborators
[121], highlighted the central role of syntrophin in maintaining a sig-
nalling complex anchored to dystrophin scaffold and necessary for
proper expression and function of voltage-gated sodium channels.
These channels linked to syntrophin are thus incorporated in a
signalplex containing PMCA and nNOS, which regulates voltage-
gated sodium currents. The absence of dystrophin also modiﬁes the
expression level and gating properties of Nav1.4 channels in mdx
skeletal muscle, leading to an increased Na+ concentration under
the sarcolemma [122]. In mdx muscle, the analysis of Nav1.4 distri-
bution suggested that syntrophin is an important linker between
dystrophin and Nav1.4. The idea that dystrophin/syntrophin com-
plex interacts with ion channels and regulates the channel function
was also proposed for non-voltage-gated calcium channels in skele-
tal muscle. Native TRPC1 channels were shown to be associated to
the dystrophin/syntrophin complex [123], as well as TRPC4 channels
[124], and α1-syntrophin was shown to play a key role through PDZ
domain on regulation of store-operated calcium entry [124], sup-
ported by TRPC1 and TRPC4 in skeletal myotubes. Through a VTTRL
motif, TRPC4 binds to the PDZ domain of the scaffolding protein
Na+/H+ Exchanger Regulatory Factor, NHERF [125]. This motif pres-
ent in TRPC4 could account for the association between the TRPC tet-
rameric channel and the PDZ domain of α1-syntrophin, which was
shown to capture TRPC1 and TRPC4 in pull-down assays [123,124].
Moreover, α1-syntrophin was essential for a PLC-dependent-
regulation of store-operated calcium entry in mouse and human
639B. Constantin / Biochimica et Biophysica Acta 1838 (2014) 635–642skeletal myotubes [126,127], and PLCγ was shown to be associated
with α1-syntrophin [126]. These observations provided the idea
that TRPC1/C4 channels association with syntrophin and PLCγ
could constitute a signalling complex anchored to dystrophin at
costameric membrane domains, which regulates the function of the
TRPC channel. In accordance with a costameric DAPC including
TRPC1 at the sarcolemma, Gervasio and collaborators reported the as-
sociation of TRPC1 with the scaffolding protein caveolin-3, by showing
co-localization at the sarcolemma and co-immunoprecipitation of en-
dogenous proteins [128]. Moreover, this work suggested by FRET
assay and coexpression of TRPC1-CFP with caveolin-3-YFP, that the lat-
ter is necessary for the localization of TRPC1 at the plasmamembrane of
myoblasts. The regulation of the TRPC signalplex by DAPC may have a
critical role in maintaining sub-plasma membrane calcium homeosta-
sis. Regulated calcium entry through TRPC may create a calcium
microdomain underneath the plasma membrane, which will regulate
for instance the activity of membrane-associated enzymes such as
calpain. This can explain calcium alteration observed in dystrophin de-
ﬁcient skeletal muscle cells with elevated calcium entry, high calcium
concentration sub-membrane microdomain and higher proteolysis ac-
tivity [129]. However, no myopathy is associated with syntrophin de-
pletion [99,100] suggesting either this function is compensated by
another signalplex, or this pathway is not crucial for striated muscle
survival. However, over expression of a TRPC channel and increase in
associated calcium entry in mouse expressing dystrophin was shown
to be sufﬁcient for inducing dystrophic phenotype [130].
The PDZ domain of syntrophin was also shown to interact directly
with other non-voltage gated channels such as mechanosensitive Na+
channels [131], as shown by pull-down experiments using the PDZ do-
main of γ2-syntrophin and the C-terminus of the mechanosensitive
Na+ channel. Interaction with γ2-syntrophin and its PDZ domain was
shown to regulate sodium currents in human jejuna circular smooth
muscle cells, and was proposed to determine mechanosensitivity andnNOS
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Fig. 1. Different interactions between the dystrophin complex and signalling molecules organi
volved in binding extracellular components and binds to dystrophin through the C-terminal dom
in the activation of Rac1 and PAK1 and of JNK/c-Jun pathways. Syntrophin can also interactwith
can also regulate sodium homeostasis through the binding of NaV1.5 voltage-gated sodium cha
channels and also PMCA. The calcium pump PMCA is also interacting with nNOS, regulating the
with the PDZ domain. The PDZ domain of α-syntrophin regulates the activity of SCN5A sodium
caveolin-3. Voltage-gated sodium channels linked to syntrophin are thus incorporated in a signa
channels. Heterotrimeric G-proteINS also interact with syntrophin, which may regulate G protcurrent availability. The presence of a consensus PDZ domain binding
motif (SNV) at the C-terminal domain of the potassium channel Kir4.1
was also shown to be involved in interaction with the PDZ domain of
α-syntrophin [132]. This interaction mediates the binding of the in-
wardly rectifying potassium channel to the dystrophin-associated com-
plex at glial cells plasma membrane, and is required for correct
distribution at precise membrane subdomains. This may have physio-
logical consequence since potassium channels in glial cells are known
to be implicated in extracellular potassium homeostasis in the central
nervous system [133]. Syntrophin and its PDZ domain were also impli-
cated in the plasma membrane distribution of Aquaporin-4 (AQP4), a
channel protein mediating water ﬂows. AQP4 c-terminal domain con-
tains the sequence Ser-Ser-Val (-SSV), which potentially binds to PDZ
domain [134], and expression of AQP4 is drastically reduced in skeletal
muscle cells of dystrophin-deﬁcientmdxmice [135]. The polarized dis-
tribution of AQP4 in the brain is altered inα-syn−/−mice, and AQP4 ex-
pression is markedly reduced in astrocytes endfeet membrane adjacent
to blood vessels in the cerebellum and cerebral cortex [136]. This study
showed that subcellular localization of AQP4 depends on association
with the dystrophin complex, through a (-SSV)-PDZ-mediated inter-
action with α-syntrophin. In the brain, the polarized expression of
AQP4 in astrocytes may be important for water homeostasis and
works in concert with inwardly rectifying K+ channels to allow
maintaining potassium homeostasis during high neuronal activity. The
syntrophin/dystrophin complex interacting with both channels may
thus play a critical role for these functions supported by astrocytes.
3. Conclusive remarks
Since the discovery of dystrophin and its associated complex, num-
ber of studies highlighted the role of dystrophin-associated complex,
especially in striated muscle, in mechanoprotection of plasma mem-
brane. It is now well established that dystrophin-associated complexGrb2
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ain of β-dystroglycan. This latter through interactionwith Grb2 and Sos1 can be involved
this intracellular signalling pathway. Syntrophins, bound to dystrophin throughSUdomain
nnels via its PDZ domain, and calcium homeostasis through interaction with TRPC1/TRPC4
activity of the enzyme, which is anchored and targeted by syntrophin through interaction
channels, and of calcium inﬂux through TRPC1/TRPC4 channels which also interact with
lplex containing PMCA and nNOS, whichmay also interact functionally with TRPC1/TRPC4
ein-coupled receptor function and have consequences on calcium homeostasis also.
640 B. Constantin / Biochimica et Biophysica Acta 1838 (2014) 635–642plays a crucial role for numerous signalling pathways, and that the
adaptor proteins syntrophin contribute to recruit and regulate various
signalling proteins such as ion channels, into a macromolecular com-
plex (Fig. 1). Although dystrophin and dystroglycan can be directly in-
volved in signalling pathways, syntrophins play a central role in
organizing signalplex anchored to the dystrophin scaffold. The dystro-
phin associated complex, can bind up to four syntrophins through the
binding domains of dystrophin and dystrobrevin, allowing the scaffold
of multiple signalling proteins in close proximity. Multiple interactions
mediated by PH and PDZ domains of syntrophin also contribute to build
a complete signalplex whichmay include ion channels, such as voltage-
gated sodium channels or TRPC cation channels, together with G
protein-coupled receptor, plasma membrane calcium pump, and NOS,
to enable an efﬁcient and regulated signal transduction and ion
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